Thursday, April, 18, 2019 08:50:23
  • The clinical data would be coming from the company’s phase-2 ampreloxetine clinical trials.
  • The 20-week-long data supports a previously announced medical observation after approximately four weeks of therapy.

Theravance Biopharma, Inc., (Theravance Biopharma), a renowned diversified biopharmaceutical company, has reportedly announced the outcome of the company’s phase-2 study of ampreloxetine (TD-9855) which will be presented at the 32nd European Neurology Congress (ENC).

Reports cite, Ampreloxetine is a once-daily, investigational Norepinephrine Reuptake Inhibitor (NRI) that is in development for treating individuals suffering from symptomatic neurogenic Orthostatic Hypotension (nOH).

According to a press release by Theravance Biopharma, the oral presentation scheduled at the ENC would be highlighting the safety, tolerability and efficacy from the company’s phase-2 clinical trial, which also includes the outcome of a 20-week-long ampreloxetine treatment. The 20-week-long data supports a previously announced medical observation after approximately four weeks of therapy.

The company had previously announced the positive results from its 4-week-long phase-2 clinical trial. The findings showcased durable enhancements in the nOH symptom-severity as calculated by OSHA #1.

The patients that were treated inside the extension phase of the clinical study depicted a mean symptom improvement of approximately 2.4 points during the four weeks. More importantly, the improvement in mean symptom was the highest (3.8 points) inside nOH patients that reported dizziness at the baseline.

Moreover, ampreloxetine also increased the standing-systolic blood pressure during the three-minute assessment on all of the weekly visits to the clinic at all of the timepoints. There were no serious adverse effects reported and the drug was generally tolerated well during the trial.

The Chief Medical Officer at Theravance Biopharma, Brett Haumann, MD, stated that the selection of the company’s phase-2 clinical trial data at the 32nd European Neurology Congress demonstrates    the drug’s potential impact on crucial unmet medical needs.

According to reports, exact schedule of oral presentation of the clinical trial results, during the July 22-24, 2019 event in London, has not been unveiled yet.